Skip to main content

Table 2 Correlation between pfdhfr / pfdhps genotypes and treatment outcomes to sulphadoxine-pyrimethamine

From: Two novel mutations of pfdhps K540T and I588F, affecting sulphadoxine-pyrimethamine-resistant response in uncomplicated falciparum malaria at Banjar district, South Kalimantan Province, Indonesia

pfdhfr*/pfdhps** genotypes

Prevalence (%) (n = 24)

Treatment outcomes

ACPR

ETF

LPF

ANCN I/SAKAA

1 (4.1)

1

  

ANRN I/SGE AA

4 (16.7)

2

1

1

ANRN I/SGE AA(588F)

5 (20.8)

1

2

2

ANRN I/SGTG A

6 (25.0)

 

2

4

ANRNL/SG KAA

4 (16.7)

2

1

1

ANRNL/SGTG A

4 (16.7)

 

4

 
  1. *pfdhfr genotypes are presented at amino acid positions of 16, 51, 59, 108, and 164.
  2. **pfdhps genotypes are presented at amino acid positions of 436, 437, 540, 581, and 613 (and 588).
  3. The bold type indicates amino acid substitution.
  4. ACPR = adequate clinical parasitological response; LPF = late parasitological failure, ETF = early treatment failure.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us